Oral Cancer Screening and Testing
Defines BCBSNM laboratory reimbursement criteria for oral cancer–related testing, including HPV tumor status tests for oropharyngeal squamous cell carcinoma; affects providers submitting claims to Blue Cross and Blue Shield of New Mexico.
Revised reimbursement information to specify intent of test: 'To establish HPV tumor status…' and updated reimbursable test modalities.
Added code 0429U and removed code 87623 from the procedure code list.
Document updated with literature review and references revised (some added, some updated, others removed).
Coverage Criteria
HPV tumor status testing coverage
Reimbursement may be available when testing is used to establish HPV tumor status in oropharyngeal squamous cell carcinoma.
ALL of the following
- High-risk HPV testing via mRNA E6/E7 expression testing.
- Immunohistochemistry for high-risk HPV.
Procedure Codes and Coding Expectations
| 0429U | Added — specific testing code referenced as added in update history |
| 87623 | Removed — previously listed code removed per update history |
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.